EUVIMEDEUVIMED entdecken
Open Access

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer

Beth K Neilsen, Rong Rong Huang, Luca F Valle, James A Proudfoot, Elai Davicioni, Liying Zhang, Una Ryg, Melanie Schulz-Jaavall, Joanne B Weidhaas, Milisuryani Santoso, Sophia Parmisano, Jeremie Calais und 9 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-03 · 124 (3) · 647-650

DOI: 10.1016/j.ijrobp.2025.09.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-03. Verfasst von Beth K Neilsen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Gene Expression Profiling, Radiation Tolerance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NLM NIH HHS, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The biology of locally radiorecurrent prostate cancer (LRR-PCa) is poorly understood. METHODS AND MATERIALS: We sought to explore the genomic and transcriptomic landscape of LRR-PCa with targeted DNA sequencing and RNA expression analysis from 41 biopsy-proven LRR-PCa tumors from 36 unique patients who had a recurrence at a median interval of 84 months (IQR, 70-124 months). Genomic alteration frequencies and transcriptomic data were compared between the LRR-PCa cohort and treatment-naïve patients from the Cancer Genome Atlas (genomic; n = 496) and Gleason grade-at-recurrence-matched patients from the Decipher Genomics Resource for Intelligent Discovery (transcriptomic; n = 22,320). RESULTS: Twenty-five patients (69%) had pathologic upgrading at recurrence (17% vs 64% with Gleason grade 4-5 disease; P < .001). The LRR-PCa cohort demonstrated significantly greater single-nucleotide variations in 29 genes known to be associated with prostate cancer, including several associated with increased aggressiveness and DNA repair: FAT1 (58.5% vs 1.0%), RAD51B (36.6% vs 0.4%), POLQ (34.1% vs 1.4%), KMT2C (34.1% vs 4.9%), BRCA2 (29.3% vs 1.8%), ATRX (26.8% vs 0.8%), and BRCA1 (24.4% vs 0.4%) (Pvalues < .001 for all). The LRR-PCa cohort had a significantly higher Decipher score (median, 0.80 vs 0.66; P = .05) and demonstrated significantly greater basal subtype based on PAM50 (56% vs 20%; P < .001) and lower androgen receptor activity (61% for LRR vs 9%; P < .001). CONCLUSIONS: Overall, these results suggest that LRR-PCa has a distinct genomic and transcriptomic landscape from de novo prostate cancer. Specifically, LRR-PCa has an enrichment in SNVs in genes associated with tumor aggressiveness and/or DNA repair, has higher Decipher scores, a more basal subtype, and has transcriptomic evidence of lower androgen receptor activity and loss of tumor suppressor genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalGene Expression ProfilingRadiation ToleranceTranscriptomeHumansMaleAgedMiddle AgedGenomicsNeoplasm GradingDNA RepairReceptors, Androgen

Substanzen

Receptors, Androgen

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
  • Department of Pathology, University of California, Los Angeles, Los Angeles, California.
  • Veracyte Inc, San Diego, California.
  • Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Ahmanson Translational Theranostics Division, University of California, Los Angeles, Los Angeles, California.

Förderung

  • NCI NIH HHS
  • NLM NIH HHS
  • U.S. Department of Defense
  • National Library of Medicine
  • US Department of Defense Prostate Cancer Research Program
  • American Society of Clinical Oncology
  • Conquer Cancer Foundation

Zitieren

APA

Neilsen, B. K., Huang, R. R., Valle, L. F., Proudfoot, J. A., Davicioni, E., Zhang, L., Ryg, U., Schulz-Jaavall, M., Weidhaas, J. B., Santoso, M., Parmisano, S., Calais, J., Reiter, R. E., Rettig, M. B., Steinberg, M. L., Sisk, A., Brisbane, W., Marks, L. S., Boutros, P. C., …, & Kishan, A. U. (2026). Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics, 124(3), 647-650. https://doi.org/10.1016/j.ijrobp.2025.09.035

Vancouver

Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, et al. Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 2026;124(3):647-650. doi:10.1016/j.ijrobp.2025.09.035

BibTeX
@article{Neilsen2026,
  author = {Neilsen, Beth K and Huang, Rong Rong and Valle, Luca F and Proudfoot, James A and Davicioni, Elai and Zhang, Liying and Ryg, Una and Schulz-Jaavall, Melanie and Weidhaas, Joanne B and Santoso, Milisuryani and Parmisano, Sophia and Calais, Jeremie and Reiter, Robert E and Rettig, Matthew B and Steinberg, Michael L and Sisk, Anthony and Brisbane, Wayne and Marks, Leonard S and Boutros, Paul C and Lilleby, Wolfgang H and Kishan, Amar U},
  title = {Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {124},
  number = {3},
  pages = {647--650},
  doi = {10.1016/j.ijrobp.2025.09.035}
}
Kostenlos starten →